# OnCo record nct04502394 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04502394/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04502394", "NCT04502394" ;
  schema:name "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL"@en ;
  schema:description "A phase 1/2 trial of KRT-232, Acalabrutinib in diffuse large b-cell lymphoma and hodgkin lymphoma, run by Kartos Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04502394/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04502394> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-02-23" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/acalabrutinib/> ;
  onco:companies <https://onco.cc/companies/kartos-therapeutics/> .